HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research Refutes Rx-Only Pseudoephedrine Requirements

This article was originally published in The Tan Sheet

Executive Summary

Research shows Rx requirements “do not effectively reduce methamphetamine’s overall impact on a given state,” CHPA President Scott Melville says. One study found Oregon’s Rx-only law has not dramatically reduced meth lab incidents compared to other states and the second showed the requirement would cost Oklahoma $59 million annually.

You may also be interested in...



Mississippi PSE Prescription Switch Will Not Start An Avalanche - CHPA

Mississippi lawmakers' decision to make all pseudoephedrine-containing drugs prescription-only will not prompt other states combating methamphetamine to do the same, the Consumer Healthcare Products Association predicts

State Pseudoephedrine Proposals Go Above, Beyond Combat Meth Act

The National Association of Chain Drug Stores has "concerns" with state bills proposing the establishment of real-time electronic repositories to monitor and limit pseudoephedrine sales, according to the trade group

Coalition Pushes Congress On OTC Purchases With Health Savings Accounts

The Health Choices Coalition sent letters urging House and Senate members to support legislation that would strike the health care reform law requirement that consumers obtain a prescription in order to purchase OTCs with a pre-tax savings account.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel